國家衛生研究院 NHRI:Items for Author
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 865108      Online Users : 673
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version

    Category

    Loading community tree, please wait....

    Year

    Loading year class tree, please wait....

    Items for Author "Bai, LY" 

    Return to Browse by Author

    Showing 40 items.

    Collection Date Title Relation Bitstream
    [其他] 期刊論文 2024-01 Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study -
    [姜乃榕] 會議論文/會議摘要 2023-06 Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors -
    [姜乃榕] 會議論文/會議摘要 2022-02 Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors -
    [姜乃榕] 會議論文/會議摘要 2021-09 A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer -
    [姜乃榕] 會議論文/會議摘要 2021-05 TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma -
    [姜乃榕] 會議論文/會議摘要 2021-05 A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy -
    [姜乃榕] 會議論文/會議摘要 2016-02 Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy -
    [姜乃榕] 期刊論文 2022-09-15 Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin -
    [姜乃榕] 期刊論文 2022-09 A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study -
    [姜乃榕] 期刊論文 2022-06 Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin -
    [姜乃榕] 期刊論文 2022-04-15 The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan -
    [楊奕馨] 期刊論文 2021-11-30 Survival outcomes of management in metastatic gastric adenocarcinoma patients -
    [潘秀玲(2009-2013)] 期刊論文 2011-12 Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma -
    [蔡慧珍] 期刊論文 2024-07-11 Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study -
    [蕭金福] 會議論文/會議摘要 2022-11 BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma -
    [蘇勇曄] 期刊論文 2024-06 Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation -
    [蘇勇曄] 期刊論文 2022-11-15 The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma -
    [蘇勇曄] 期刊論文 2021-11-20 Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study -
    [陳立宗] 會議論文/會議摘要 2022-07 A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer -
    [陳立宗] 會議論文/會議摘要 2022-02-01 A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma -
    [陳立宗] 會議論文/會議摘要 2020-09 Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study -
    [陳立宗] 會議論文/會議摘要 2020-02 Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study -
    [陳立宗] 期刊論文 2024-08-20 Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri -
    [陳立宗] 期刊論文 2024-08-06 Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer -
    [陳立宗] 期刊論文 2024-05 Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer -
    [陳立宗] 期刊論文 2023-08 The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study -
    [陳立宗] 期刊論文 2023-02-05 Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer -
    [陳立宗] 期刊論文 2022-10 Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study -
    [陳立宗] 期刊論文 2022-06-22 Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study -
    [陳立宗] 期刊論文 2022-02 Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr -
    [陳立宗] 期刊論文 2022-01 Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study -
    [陳立宗] 期刊論文 2021-10 Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study -
    [陳立宗] 期刊論文 2021-07 Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab -
    [陳立宗] 期刊論文 2020-12-29 Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan -
    [陳立宗] 期刊論文 2020-05 A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data -
    [陳立宗] 期刊論文 2020-01 Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer -
    [陳立宗] 期刊論文 2019-10 A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO -
    [陳立宗] 期刊論文 2017-12 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial -
    [陳立宗] 期刊論文 2015-05 A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer -
    [黃秀芬] 期刊論文 2021-07 Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback